Abstract: Disclosed are pharmaceutical compositions comprising a therapeutically effective amount of a first compound, wherein the first compound binds the heparin-binding domain of the vascular endothelial growth factor (VEGF); and a therapeutically effective amount of a second compound, wherein the second compound binds to VEGF, thereby inhibiting the binding of VEGF to its cognate receptor. Also disclosed are methods of treating a VEGF-related disorder in a subject, the method comprising identifying a subject in need thereof, and administering to the subject a therapeutically effective amount of a first compound, wherein the first compound binds the heparin-binding domain of the vascular endothelial growth factor (VEGF); and a therapeutically effective amount of a second compound, wherein the second compound binds to VEGF, thereby inhibiting the binding of VEGF to its cognate receptor.

Abstract: This invention relates to an NSO myeloma cell line which has increased fusion frequency, and to a method of producing said cell line. The NSO cell line of the invention, when fused with B cells, produces monoclonal antibody-secreting hybridoma which has increased resistance to death. In addition, the monoclonal antibodies secreted by said hybridomas have increased affinity for foreign antigens and for autoantigens.